Cargando…

Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease

INTRODUCTION: Therapeutic options are critically needed for children with refractory very early onset inflammatory bowel disease (VEO-IBD). Our aim was to evaluate clinical response to canakinumab, an anti-IL-1β monoclonal antibody, in patients with VEO-IBD whose phenotype resembles those with monog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaul, Eliana, Conrad, Máire A., Dawany, Noor, Patel, Trusha, Canavan, Megan C., Baccarella, Alyssa, Weinbrom, Sarah, Aleynick, Daniel, Sullivan, Kathleen E., Kelsen, Judith R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531243/ https://www.ncbi.nlm.nih.gov/pubmed/36203564 http://dx.doi.org/10.3389/fimmu.2022.972114

Ejemplares similares

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

A de novo whole gene deletion of XIAP detected by exome sequencing analysis in very early onset inflammatory bowel disease: a case report
por: Kelsen, Judith R., et al.
Publicado: (2015)

Erratum to: A de novo whole gene deletion of XIAP detected by exome sequencing analysis in very early onset inflammatory bowel disease: a case report
por: Kelsen, Judith R., et al.
Publicado: (2015)

Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders
por: Alkan, Arif, et al.
Publicado: (2022)

H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus
por: Zhang, Zhe, et al.
Publicado: (2016)

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study
por: Alexeeva, Ekaterina, et al.
Publicado: (2023)

Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network
por: Gaggiano, Carla, et al.
Publicado: (2021)

Maintaining Intestinal Health: The Genetics and Immunology of Very Early Onset Inflammatory Bowel Disease
por: Kelsen, Judith R., et al.
Publicado: (2015)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
por: Galozzi, Paola, et al.
Publicado: (2018)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Systemic autoinflammatory disorders: autoinflammatory and autoimmune disorders
por: Kim, Young Dae
Publicado: (2023)

Very early-onset inflammatory bowel disease: Novel description in glycogen storage disease type Ia
por: Hannah, William B., et al.
Publicado: (2022)

The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases
por: Gaggiano, Carla, et al.
Publicado: (2022)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab for refractory RA: a case report
por: Marketos, Nikolaos, et al.
Publicado: (2018)

Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et al
por: Brunner, Hermine, et al.
Publicado: (2015)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020)

The patient journey to diagnosis and treatment of autoinflammatory diseases
por: Hausmann, Jonathan S., et al.
Publicado: (2018)

P02-008 - Dramatic response to canakinumab in MKD
por: Makay, B, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Clinical response to the canakinumab in crohn’s disease related artrhritis
por: Gündüz, Zübeyde, et al.
Publicado: (2014)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

Isolation of Epithelial and Stromal Cells from Colon Tissues in Homeostasis and Under Inflammatory Conditions
por: Morral, Clara, et al.
Publicado: (2023)

An Update on Autoinflammatory Diseases
por: Ciccarelli, F., et al.
Publicado: (2013)

Systemic autoinflammatory diseases
por: Krainer, Julie, et al.
Publicado: (2020)

Autoinflammatory Diseases in Childhood
por: Yıldız, Mehmet, et al.
Publicado: (2020)

Rare Autoinflammatory Diseases
por: Başaran, Özge, et al.
Publicado: (2022)

Macroglobulinemia and Autoinflammatory Disease
por: Navetta-Modrov, Brianne, et al.
Publicado: (2021)

Systemic autoinflammatory disorders
por: Jeong, Dae Chul
Publicado: (2023)

Autoinflammatory diseases and the kidney
por: Hegazy, Mohamed Tharwat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t3ne374potc285s2n1mi9lapdm